At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
PAN-301-1biological
Likely dose
Not stated in record
Key inclusion· 7
- ✓Men aged 21–85 years with histologically confirmed prostate cancer and biochemical relapse after definitive local therapy (surgery or radiation).
- ✓Biochemically relapsed disease defined as PSA >2 ng/mL 1 year post-treatment, or PSA doubling time <12 months, or PSA velocity >2 ng/mL/year.
- ✓Positive HAAH expression in archived tumor tissue or fresh serum.
- ✓No clinical or radiologic evidence of distant metastatic disease on pelvic MRI/CT or bone scan (within 56±7 days of study start).
Key exclusion· 8
- ✕PSA doubling time <3 months.
- ✕Prior major surgery or radiation therapy within 4 weeks of enrollment.
- ✕Prior cytotoxic chemotherapy for current cancer.
- ✕Active autoimmune disease (requiring immune suppressive or cytoreductive therapy currently or within 1 year).
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1, Open Label Trial to Evaluate the Safety and Immunogenicity of PAN-301-1 in Cancer Patients
In Brief
A Phase 1 clinical trial evaluating PAN-301-1 for Prostate Cancer. Completed, enrolled 12 participants across 4 sites.
Detailed Summary
This is a Phase I, open-label, parallel design study of PAN-301-1 (SNS-301), a HAAH directed nanoparticle vaccine, given intradermally in cohorts of patients with biochemically relapsed prostate cancer, using a fixed dose escalation schema every 21 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsAccelovance
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartDec 2016
First PostedApr 2017
Primary CompletionDec 2018
TodayJul 2026
First PostedApr 19, 2017
Enrollment StartDec 1, 2016
Primary CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 9.2 years ago
Interventions
PAN-301-1biological